Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

AHCPR GUIDELINE ON MANAGEMENT OF CANCER-RELATED PAIN in clinical practice is currently targeted for release this autumn, HHS' Agency for Health Care Policy and Research said. The agency currently has 15 clinical practice guidelines on its schedule for dissemination in 1993 and 1994. Guidelines on the initial evaluation and early treatment of HIV-positive individuals and on the treatment and diagnosis of benign prostatic hyperplasia are anticipated out this summer. Furthest along is a guide on sickle cell disease in newborns and infants, which is scheduled for release April 27. Among the documents to be unveiled in 1993 is a guideline on quality determinants of mammography. Other guides targeted for release some time this year cover the care and evaluation of heart failure; lower back problems (anticipated ready in the late summer/early fall); post-stroke rehabilitation; screening for Alzheimer's and related dementias; and treatment of pressure ulcers in adults. Next year, the HHS agency hopes to have ready clinical practice guidelines on chest pain due to unstable angina; cardiac rehabilitation services; anxiety and panic disorders in primary care; and smoking prevention and cessation. The agency recently released its fifth guideline, which covers depression in the primary care setting.

You may also be interested in...

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

HBW Product Launches: VitaFusion Goodness, Colgate Zero, Tom’s Prebiotic, Gaia Hemp & Herb

Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts